Login to Your Account



BIO CEO & Investor Conference

Keep exits clear, plans aligned to take advantage of M&A opportunities

By Jennifer Boggs
Managing Editor

Tuesday, February 13, 2018

NEW YORK – Coming off a slower-than-usual year in biopharma M&A activity – due largely to drug pricing pressures and regulatory uncertainty, coupled with a robust financing environment – many industry observers have tagged 2018 to be a busy year in acquisitions.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription